Is Zepbound the Same as Ozempic? No, Here's the Full Comparison

Key Takeaways

• Zepbound and Ozempic are different medications. Zepbound contains tirzepatide, a dual GLP-1/GIP receptor agonist made by Eli Lilly. Ozempic contains semaglutide, a single GLP-1 receptor agonist made by Novo Nordisk.
• Zepbound is FDA-approved for chronic weight management. Ozempic is FDA-approved for type 2 diabetes (not weight loss). Wegovy is the weight loss-approved version of semaglutide.
• Tirzepatide produces more weight loss on average than semaglutide. SURPASS-2 head-to-head data showed 12.4 kg loss for tirzepatide 15 mg vs 6.2 kg for semaglutide 1 mg over 40 weeks (Frias et al., NEJM 2021).
• Both drugs share common side effects (nausea, GI distress) but the dual mechanism in Zepbound produces slightly different tolerability profiles.
• Insurance, cost, and supply differ significantly between the two. Brand-name pricing for both is $1,000+ monthly without coverage; compounded versions of either active ingredient are typically lower cost.

Direct answer (40-60 words)

No, Zepbound and Ozempic are not the same. Zepbound contains tirzepatide and works on both GLP-1 and GIP receptors. Ozempic contains semaglutide and works on GLP-1 receptors only. They're made by different manufacturers (Lilly vs Novo Nordisk), have different FDA-approved indications, and produce different weight loss outcomes in clinical trials.

Table of contents

1. The 30-second answer
2. Active ingredient: tirzepatide vs semaglutide
3. Mechanism: dual receptor vs single receptor
4. FDA-approved indications
5. Side-by-side comparison table
6. Weight loss outcomes head-to-head
7. Side effects: similar profile, different intensities
8. Dosing schedules
9. Cost and insurance differences
10. Compounded versions of each
11. Which one might be right for which patient
12. FAQ
13. Sources
14. Footer disclaimers

Active ingredient: tirzepatide vs semaglutide

The most important difference is the active pharmaceutical ingredient.

Zepbound = tirzepatide. A 39-amino-acid synthetic peptide engineered by Eli Lilly. Tirzepatide is a "dual agonist," meaning it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor.

Ozempic = semaglutide. A 31-amino-acid modified GLP-1 peptide made by Novo Nordisk. Semaglutide activates only the GLP-1 receptor.

The two molecules have different structures, bind to different receptor combinations, and produce different downstream effects. They're both classified as "GLP-1-based therapies," but pharmacologically they're distinct drugs.

Wegovy is also semaglutide. It's the same active ingredient as Ozempic but at higher doses and labeled for chronic weight management. Mounjaro is also tirzepatide, the diabetes-labeled version of the same active ingredient that's in Zepbound.

Brand name	Active ingredient	Manufacturer	FDA approval
Ozempic	Semaglutide	Novo Nordisk	Type 2 diabetes
Wegovy	Semaglutide	Novo Nordisk	Chronic weight management
Mounjaro	Tirzepatide	Eli Lilly	Type 2 diabetes
Zepbound	Tirzepatide	Eli Lilly	Chronic weight management

So Zepbound is to tirzepatide what Wegovy is to semaglutide: the obesity-labeled version of the same active ingredient. Comparing Zepbound to Ozempic is comparing two different active ingredients with different brand families.

Mechanism: dual receptor vs single receptor

The mechanism difference is the most consequential difference between the two drugs.

Semaglutide (Ozempic): activates the GLP-1 receptor only. GLP-1 receptors are present in the pancreas, stomach, intestines, brain (specifically the hypothalamus and brainstem), and other tissues. Activation produces:

• Increased insulin secretion (glucose-dependent)
• Decreased glucagon secretion
• Slowed gastric emptying
• Reduced appetite via brain receptor activation

Tirzepatide (Zepbound): activates both the GLP-1 receptor and the GIP receptor. GIP is another incretin hormone with overlapping but distinct effects. Activation of both receptors produces:

• All of the GLP-1 effects above
• Plus GIP-mediated effects on insulin secretion, glucose handling, and possibly fat metabolism
• Plus apparent enhanced weight loss compared to GLP-1 alone

The GIP receptor's role in weight loss has been somewhat surprising in research. GIP was originally thought to be obesity-promoting based on knockout mouse studies. But synthetic GIP receptor agonists in humans appear to enhance rather than block weight loss when paired with GLP-1 activation.

A 2022 paper in Cell Metabolism (Drucker, 2022) reviewed the GIP-receptor pharmacology and concluded that the dual mechanism produces additive effects on insulin sensitivity, appetite suppression, and lipid metabolism. The clinical effect is the larger weight loss seen in tirzepatide trials vs semaglutide trials.

FDA-approved indications

The FDA has approved different versions of each active ingredient for different uses.

Zepbound (tirzepatide). Approved November 2023 for chronic weight management in adults with:

• BMI of 30 or higher (obesity), OR
• BMI of 27 or higher with at least one weight-related condition (high blood pressure, type 2 diabetes, dyslipidemia)

Ozempic (semaglutide). Approved 2017 for:

• Type 2 diabetes (improving glycemic control alongside diet and exercise)
• Reducing risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease

Mounjaro (tirzepatide). Approved May 2022 for:

• Type 2 diabetes (improving glycemic control)

Wegovy (semaglutide). Approved June 2021 for:

• Chronic weight management in adults with same criteria as Zepbound
• Cardiovascular risk reduction in adults with established cardiovascular disease and overweight/obesity (added 2024)

If you're being prescribed one of these drugs for weight loss, it should be Zepbound or Wegovy, not Ozempic or Mounjaro. The diabetes-labeled versions are sometimes prescribed off-label for weight loss but this is not the FDA-approved use.

Side-by-side comparison table

Feature	Zepbound	Ozempic
Active ingredient	Tirzepatide	Semaglutide
Manufacturer	Eli Lilly	Novo Nordisk
Receptor mechanism	Dual GLP-1 + GIP	GLP-1 only
FDA approval	Chronic weight management	Type 2 diabetes
Approved for weight loss?	Yes	No (Wegovy is)
Dosing schedule	2.5 mg weekly, titrating to 15 mg max	0.25 mg weekly, titrating to 2 mg max
Pen format	Auto-injector pen, 4 doses per pen	Auto-injector pen, 4 doses per pen
Average weight loss in trials	22.5% at 72 weeks (15 mg, SURMOUNT-1)	14.9% at 68 weeks (2.4 mg, STEP 1, semaglutide)
Cardiovascular outcomes data	Limited (SURPASS-CVOT ongoing)	Established (SUSTAIN-6 positive)
Year approved	2023 (weight), 2022 (diabetes)	2017 (diabetes)
Half-life	~5 days	~7 days
Refrigeration after use	Up to 56 days at room temp or refrigerated	Up to 56 days at room temp or refrigerated
Black box warning	Thyroid C-cell tumor risk (rodent data)	Thyroid C-cell tumor risk (rodent data)
Common pharmacy cost (without insurance)	~$1,059/month	~$998/month

The most clinically significant differences are the receptor mechanism, the FDA approval (Zepbound for weight, Ozempic for diabetes), and the average weight loss outcomes.

Weight loss outcomes head-to-head

The cleanest head-to-head comparison is SURPASS-2 (Frias et al., NEJM 2021), which compared tirzepatide vs semaglutide in patients with type 2 diabetes:

Treatment	Average weight loss at 40 weeks
Semaglutide 1 mg	6.2 kg (13.7 lb)
Tirzepatide 5 mg	7.6 kg (16.8 lb)
Tirzepatide 10 mg	9.3 kg (20.5 lb)
Tirzepatide 15 mg	11.2 kg (24.7 lb)

Tirzepatide outperformed semaglutide at every comparable dose level. The 15 mg tirzepatide dose produced almost double the weight loss of the 1 mg semaglutide dose.

For weight management specifically, comparing across trials (not head-to-head):

• SURMOUNT-1: tirzepatide 15 mg produced 22.5% weight loss at 72 weeks
• STEP 1: semaglutide 2.4 mg produced 14.9% weight loss at 68 weeks

Tirzepatide produces more weight loss on average. Individual response varies, and some patients respond better to semaglutide. The only way to know for sure is to try one and assess after 12 to 16 weeks.

Side effects: similar profile, different intensities

Both drugs share the GLP-1 side effect profile because both activate GLP-1 receptors. The most common side effects are gastrointestinal:

• Nausea (most common, especially during titration)
• Vomiting
• Diarrhea or constipation
• Decreased appetite (a desired effect)
• Stomach pain or fullness
• Heartburn / acid reflux
• Headache
• Fatigue
• Injection site reactions

The intensity differs slightly between the two:

Side effect	Tirzepatide (Zepbound)	Semaglutide (Wegovy)
Nausea	24-33% (dose-dependent)	44%
Vomiting	10-13%	24%
Diarrhea	19-23%	30%
Constipation	11-17%	24%
Discontinuation due to AEs	6-7%	6%

Tirzepatide has somewhat lower rates of nausea and vomiting in trials, possibly because the GIP receptor activity may attenuate some of the GI effects of GLP-1 alone. Both drugs have similar discontinuation rates due to side effects.

Serious side effects (uncommon for both):

• Pancreatitis (precaution)
• Gallbladder disease (especially during rapid weight loss)
• Acute kidney injury (related to dehydration from vomiting)
• Severe hypoglycemia (mostly in patients also taking sulfonylureas or insulin)
• Diabetic retinopathy worsening (semaglutide signal in SUSTAIN-6)
• Allergic reactions (rare but possible)

Dosing schedules

The titration schedules are different.

Zepbound (tirzepatide):

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg
• Weeks 9-12: 7.5 mg
• Weeks 13-16: 10 mg
• Weeks 17-20: 12.5 mg
• Weeks 21+: 15 mg (maximum)

Ozempic (semaglutide):

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg
• After 4 weeks at 0.5 mg: increase to 1 mg as needed
• After 4 weeks at 1 mg: increase to 2 mg as needed (max for Ozempic)

Wegovy (semaglutide for weight loss): uses higher doses, titrating up to 2.4 mg weekly over 16 weeks.

The dosing strengths aren't directly comparable because the molecules have different potencies. 1 mg semaglutide is roughly equivalent in clinical effect to about 5 mg tirzepatide, though comparisons are imprecise.

If you're switching between the two (always under provider supervision), you don't need to start over from scratch on titration, but the dose levels need to be matched approximately rather than exactly.

Cost and insurance differences

Brand-name pricing without insurance is roughly comparable:

Drug	List price (monthly)
Zepbound	$1,059
Mounjaro	$1,069
Ozempic	$998
Wegovy	$1,349

Insurance coverage varies. Some plans cover Ozempic for type 2 diabetes but not Wegovy or Zepbound for weight management. Some plans cover Zepbound or Wegovy if the patient meets specific BMI and comorbidity criteria. Coverage rules change frequently and are highly plan-specific.

Manufacturer savings cards reduce cost for some patients:

• Lilly's Zepbound savings program brings cost as low as $25-$30 per month for commercially insured patients with coverage, or up to $550 off for those without coverage.
• Novo Nordisk's Ozempic and Wegovy savings programs offer similar structures.

Compounded alternatives are typically lower cost. Compounded semaglutide programs typically run $179 to $259 per month flat. Compounded tirzepatide runs $189 to $379 per month depending on dose and provider. (See our compounded GLP-1 cost guide for current ranges.)

Compounded versions of each

The 2022 to 2024 shortages of brand-name GLP-1 medications drove patients toward compounded versions. The relevant points:

Compounded semaglutide. Same active pharmaceutical ingredient as Ozempic and Wegovy, prepared by a state-licensed compounding pharmacy in response to an individual prescription. Available because semaglutide was on the FDA shortage list from late 2022 through October 2024. The shortage was officially resolved in October 2024, which has affected the legal landscape for ongoing compounding.

Compounded tirzepatide. Same active pharmaceutical ingredient as Mounjaro and Zepbound. Tirzepatide was also on the FDA shortage list. The shortage was resolved in late 2024. Some compounding pharmacies continue to compound tirzepatide for patients with documented clinical needs that brand-name versions can't meet (specific dose strengths, allergies to inactive ingredients, etc.).

Compounded versions are not FDA-approved and are not interchangeable with brand-name products for FDA-approval purposes. The active ingredient is chemically identical but the manufacturing process, quality controls, and regulatory oversight differ.

For patients comparing Zepbound to Ozempic, compounded options exist for both active ingredients. The clinical decision (tirzepatide vs semaglutide) is the same regardless of whether you're comparing brand-name or compounded versions.

Which one might be right for which patient

Generalizations rather than rigid rules:

Tirzepatide (Zepbound or compounded) may be the better fit when:

• Goal is significant weight loss (more than 15% of body weight)
• Patient has type 2 diabetes alongside obesity (Mounjaro for diabetes, Zepbound for weight)
• Patient has tolerated semaglutide poorly with severe nausea/vomiting (the dual mechanism may produce less GI distress in some cases)
• Patient has not responded adequately to a maximum dose of semaglutide

Semaglutide (Ozempic or Wegovy or compounded) may be the better fit when:

• Patient has established cardiovascular disease (semaglutide has the most cardiovascular outcomes data)
• Patient is responding well to current treatment with no need to switch
• Cost or insurance coverage favors semaglutide
• Patient prefers a simpler titration schedule

Either is reasonable when:

• Patient is naive to GLP-1 medications and has a typical clinical picture
• Patient has BMI 30+ with no comorbidities other than obesity
• Long-term provider relationship and access matter more than maximizing weight loss percentage

Provider choice often comes down to local prescribing patterns, formulary status with the patient's insurance, and personal experience with side effect management. Both drugs are clinically reasonable choices for weight management when used appropriately.

FAQ

Is Zepbound the same as Ozempic? No. Zepbound contains tirzepatide and works on GLP-1 and GIP receptors. Ozempic contains semaglutide and works on GLP-1 receptors only. They're different drugs from different manufacturers with different FDA-approved uses.

Is Zepbound stronger than Ozempic? Yes, on average. Head-to-head data from SURPASS-2 showed tirzepatide produced more weight loss and better glycemic control than semaglutide at comparable dose levels. SURMOUNT-1 reported 22.5% average weight loss for tirzepatide 15 mg over 72 weeks vs 14.9% for semaglutide 2.4 mg in STEP 1.

Can I switch from Ozempic to Zepbound? Yes, with provider supervision. The switch isn't a 1-to-1 dose match because the molecules have different potencies. Most providers start the new drug at a lower dose than the equivalent of the previous one and titrate up to find the right level.

Are Zepbound and Mounjaro the same? Yes. Both contain tirzepatide and are made by Eli Lilly. The difference is FDA approval: Mounjaro is approved for type 2 diabetes, Zepbound is approved for chronic weight management. They're the same molecule, different brand names for different labeled uses.

Are Ozempic and Wegovy the same? Same active ingredient (semaglutide), different brand names and different FDA approvals. Ozempic is for type 2 diabetes (max dose 2 mg). Wegovy is for chronic weight management (max dose 2.4 mg). Different doses for different indications.

Which has fewer side effects, Zepbound or Ozempic? Trial data suggests tirzepatide has slightly lower rates of nausea and vomiting than semaglutide at comparable doses, though both have similar overall discontinuation rates due to side effects. Individual response varies significantly.

Is Zepbound or Ozempic safer for long-term use? Both have similar safety profiles in long-term trials. Semaglutide has more years of post-approval data because it was approved earlier. Tirzepatide has been in clinical use since 2022 and the long-term safety picture continues to develop. Both carry the same black-box warning for thyroid C-cell tumor risk.

Will Ozempic or Zepbound work better for me? There's no way to predict individual response without trying. Tirzepatide produces more weight loss on average in trials, but some patients respond better to semaglutide. Most providers recommend giving any GLP-1 medication 12 to 16 weeks at a therapeutic dose before deciding it's not working.

Can I take Zepbound and Ozempic together? No. Both activate GLP-1 receptors and combining them would substantially increase the risk of hypoglycemia, GI side effects, and pancreatitis without proportional benefit. Use one or the other, not both.

Why is Ozempic prescribed for weight loss if it's not approved for that? Off-label prescribing is legal and common when a drug has reasonable evidence for a non-approved use. Ozempic produces weight loss as a side effect, so providers sometimes prescribe it for weight management. The FDA-approved option for semaglutide-based weight loss is Wegovy.

Does compounded semaglutide equal Ozempic? Same active pharmaceutical ingredient, different manufacturing and regulatory status. Compounded semaglutide is not FDA-approved and is not legally interchangeable with brand-name Ozempic. The molecule is chemically identical but the products are different from a regulatory standpoint.

Does compounded tirzepatide equal Zepbound? Same answer as above. Same active ingredient, different regulatory status. Compounded versions of either active ingredient should be obtained from state-licensed compounding pharmacies through a legitimate prescription, not from unverified online sellers.

Sources

1. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021;385(6):503-515.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
4. FDA Zepbound Prescribing Information. Eli Lilly and Company. November 2023.
5. FDA Ozempic Prescribing Information. Novo Nordisk. December 2017, revised 2024.
6. FDA Wegovy Prescribing Information. Novo Nordisk. June 2021, revised 2024.
7. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Cell Metabolism. 2022;34(2):165-184.
8. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375(19):1834-1844.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.